About the Company
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EDIT News
Editas to present gene editing advancements at ASGCT
CAMBRIDGE, Mass. - Editas Medicine , Inc. (NASDAQ:EDIT), a leader in gene editing technology, will showcase new pre-clinical data at the upcoming American Society of Gene and Cell Therapy (ASGCT ...
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript
Gilmore O’Neill: Thanks very much. So from the in vivo pipeline point of view with regard to the how and the when, we’re excited to be on track towards POC this year for an in vivo preclinical ...
Editas Medicine gets grant for allele-specific modification of hla genes for cell transplantation
Enhance donor cell compatibility for transplantation with Editas Medicine's patented method. Reduce immunogenicity genes' expression for therapeutic benefits.
Analyst Forecast For Editas Medicine Inc (NASDAQ: EDIT)
The trading price of Editas Medicine Inc (NASDAQ:EDIT) closed lower on Tuesday, April 02, closing at $6.87, -5.63% lower than its previous close. In examining the 52-week price action we see that the ...
Editas: Q4 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Wednesday reported a loss of $18.9 million in its fourth quarter. The Cambridge, Massachusetts-based company said ...
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy ...
Editas Medicine Inc EDIT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Editas Medicine Inc (EDIT)
View the EDIT option chain and compare options of Editas Medicine Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell ...
Editas Medicine, Inc. (EDIT)
Editas (EDIT) delivered earnings and revenue surprises of 55.77% and 347.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Loading the latest forecasts...